A document-backed view of federal activity that can shape ibogaine and noribogaine research, oversight, and the boundary between investigational study and treatment access.
Use this page alongside the broader ibogaine policy and safety resource to distinguish agency activity, proposed actions, and unresolved questions from claims about available care.
Each entry should identify its date, originating body, primary document, practical meaning, and the uncertainty that remains.
A document may show investigation, guidance, funding, or enforcement posture. It does not by itself establish that ibogaine is an approved treatment or that a particular access pathway is lawful.
The FDA’s Investigational New Drug application framework is the relevant route for clinical investigation of a drug that is not approved for marketing. An IND, meeting, or development discussion does not equal a finding of safety or effectiveness, and it does not create ordinary treatment access.
Ibogaine is listed in Schedule I under the federal controlled-substances schedules, reflected in the DEA’s drug scheduling overview. That status carries research-registration and handling implications; it should not be confused with an assessment of clinical benefit.
Tracker entries should state which compound is being discussed. The ibogaine reference overview identifies ibogaine as the compound at issue, while noribogaine may appear in research and development discussions with a different scientific or regulatory context.
Track an agency notice, docket, funding announcement, bill text, guidance document, or official meeting record—not a secondary description alone.
Separate a binding rule or statutory change from a proposal, public statement, research announcement, or request for comment.
Ask whether the development changes study access, research handling, safety monitoring, or no access pathway at all. For treatment-location claims, compare the distinction with reported ibogaine treatment locations rather than assuming a federal action authorizes a service.
FDA materials may involve IND administration, formal meetings, guidance, advisory-committee records, and later labeling decisions. The agency’s drug development and approval process explains why an investigational program and an approved product are different stages with different evidence and oversight expectations.
DEA actions can include rulemaking, notices, registration matters, and scheduling records. HHS components, including NIDA, and programs such as ARPA-H may issue research priorities or funding announcements. VA guidance can affect internal policy and study activity, but should be read for its exact scope before it is treated as patient-facing authorization.
Federal attention can be consequential without changing the present legal distinction between research participation and approved treatment.
Policy interest, research activity, and a commercial claim are not interchangeable evidence categories.
No. Research activity can indicate that a question is being studied or supported; approval is a separate regulatory determination. Accounts of an ibogaine approach for PTSD treatment should therefore be read in light of the underlying study and its regulatory status, not as a substitute for it.
Ibogaine discussions often raise questions about screening, interactions, and cardiac risk. Those questions are distinct from policy momentum. Reviewing long-term side-effect discussions can help keep uncertainty and safety context visible when interpreting agency developments.
A bill, amendment, hearing, or report language should be labeled by its actual procedural position. Unless enacted or otherwise operative, it is not a change in law. The site’s approach to evidence clarity is to retain that distinction even where public attention is high.
No. Personal accounts may describe an individual experience but cannot establish legal status, research quality, or safety for others. Use an ibogaine experience report as narrative context rather than a regulatory source, and keep it separate from formal study outcomes.
Funding, policy discussion, overseas access claims, and treatment outcomes each answer different questions. A claim about ibogaine clinics in Costa Rica does not establish U.S. federal status, and a reported ibogaine success rate does not replace evidence review or regulatory analysis.
For support in reading the tracker’s categories and source hierarchy, see the available research-navigation resources. This information is not medical or legal advice.